Loading…
No business profile yet.
Size Medigen Vaccine Biologics (6547.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $467M, the 469th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$46.90 on 6 Nov 2026.
Performance Over six months the shares fell 5.3%, against -12.0% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 44.4% over the last twelve months (peer median -4.0%); the operating margin is 10.2% (peer median -27.2%).
Valuation It trades at 187.6× forward earnings against a peer median of 31.2× (most expensive of 5).
Capital Return on invested capital runs 3.4 points below its cost of capital (5.0% WACC).
Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$859M | NT$613M | NT$606M | NT$390M | NT$365M |
| Revenue growth | — | +1% | +55% | +7% | — |
| Gross profit | NT$573M | NT$312M | NT$332M | NT$221M | -NT$221M |
| EBITDA | n/a | -NT$124M | -NT$9.23M | -NT$1.08B | -NT$1.41B |
| Net income | -NT$34.9M | -NT$282M | -NT$80.5M | -NT$1.16B | -NT$1.47B |
| Free cash flow | n/a | -NT$99.7M | NT$6.46M | -NT$516M | -NT$1.24B |
| Capital expenditure | n/a | NT$51.8M | NT$35.0M | NT$41.0M | NT$140M |
| Total debt | n/a | NT$283M | NT$339M | NT$1.97B | NT$1.98B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6547.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.4% | -13.9% | 5th lowest of 21 |
| 6-month return | -5.3% | -12.0% | 10th highest of 20 |
| Distance from 52-week high | -35.0% | -40.0% | 9th highest of 21 |
| Revenue growth (TTM) | +44.4% | -4.0% | 2nd highest of 15 |
| Operating margin | 10.2% | -27.2% | 3rd highest of 16 |
| Forward P/E | 187.6× | 31.2× | most expensive of 5 |
| ROIC minus cost of capital | -3.4 pp | -15.4 pp | 2nd highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $467M | -5% | +44% | 10% | 187.6× | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $466M | -5% | n/a | n/a | n/a | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $468M | -27% | +286% | 68% | 6.3× | -14.9% | -36.1% |
| Shanghai ZJ Bio-Tech 688317.SS | China | $468M | -16% | -18% | -75% | n/a | 6.0% | -62.3% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $469M | -13% | n/a | n/a | n/a | n/a | n/a |
| Shattuck Labs STTK | United States | $464M | -33% | -67% | -5,571% | n/a | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $462M | -4% | +20% | -79% | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $460M | -12% | -3% | 2% | n/a | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $458M | +139% | n/a | n/a | n/a | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $454M | +10% | +4% | -30% | n/a | 31.8% | -3.3% |
| Monopar Therapeutics MNPR | United States | $479M | +12% | n/a | n/a | n/a | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $480M | +57% | -47% | -17,694% | n/a | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $482M | -1% | -5% | -4% | 43.8× | 15.2% | +0.5% |
| Qingdao Vland Biotech 603739.SS | China | $450M | -21% | +5% | 7% | 33.9× | 18.2% | +7.3% |
| Shanghai Shen Lian Biomedical 688098.SS | China | $444M | -18% | -17% | -16% | n/a | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $443M | -36% | -30% | -27% | n/a | n/a | n/a |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $440M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 28.6× | 5.8% | +70.5% |
| Crescent Biopharma CBIO | United States | $503M | -28% | n/a | -1,418% | n/a | n/a | n/a |
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $504M | -5% | -2% | -24% | n/a | n/a | n/a |